For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth ...

Thursday, Laboratory Corp (NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating the consensus of $3.39. Sales increased 9.8% year-over-year to ...

Principal Financial Group Inc. grew its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 0.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 95,004 ...

LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain ...

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

Labcorp Holdings Inc. LH, or Labcorp, is positioning itself for sustained growth with a series of strategic acquisitions and partnerships. With a growing emphasis on cell and gene therapy, the company ...

Shares of Labcorp Holdings Inc. LH slipped 2.56% to $253.73 Wednesday, on what proved to be an all-around rough trading ...

Detailed price information for Laboratory Corp of America Holdings (LH-N) from The Globe and Mail including charting and trades.

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

Labcorp Holdings Inc. (LH), headquartered in Burlington, North Carolina, stands as a premier global life sciences company ...